Show simple item record

dc.contributor.authorMyrdal, Caitlyn N.
dc.contributor.authorSundararajan, Srinath
dc.contributor.authorCuriel-Lewandrowski, Clara
dc.date.accessioned2021-04-03T01:36:40Z
dc.date.available2021-04-03T01:36:40Z
dc.date.issued2020
dc.identifier.citationMyrdal, C. N., Sundararajan, S., & Curiel-Lewandrowski, C. (2020). Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade. Case Reports in Dermatology, 12(2), 119-123.
dc.identifier.issn1662-6567
dc.identifier.pmid32774246
dc.identifier.doi10.1159/000508490
dc.identifier.urihttp://hdl.handle.net/10150/657598
dc.description.abstractHypertrophic lichen planus (HLP) may not have the typical histological findings of lichen planus and often mimics squamous cell carcinoma (SCC). Distinguishing between the two can pose a diagnostic challenge. Here, we present a case of eruptive HLP mimicking SCC in the context of programmed cell death ligand 1 (PD-L1) immune checkpoint inhibition. A 73-year-old woman recently treated with durvalumab, an anti-PD-L1 antibody, presented to our clinic with diffuse hyperkeratotic papules and plaques previously thought to be eruptive SCC. The lesions did not respond to topical fluorouracil and continued to appear despite discontinuation of immunotherapy. Further histological analysis revealed intraepidermal epithelial proliferation with lichenoid inflammation. Subsequent treatment with topical corticosteroids significantly improved the size and number of lesions. The diagnosis of HLP was made based on histological features and response to topical steroids in the context of recent immunotherapy. This case reveals HLP as a potential adverse effect of PD-L1 inhibition and highlights the need for additional diagnostic assessment in patients presenting with eruptive hyperkeratotic lesions, especially on the lower extremities.
dc.language.isoen
dc.publisherKARGER
dc.rights© 2020 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC).
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectAdverse drug reaction
dc.subjectHypertrophic lichen planus
dc.subjectImmunotherapy
dc.subjectProgrammed cell death ligand 1
dc.subjectSquamous cell carcinoma
dc.titleWidespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade
dc.typeArticle
dc.typetext
dc.contributor.departmentUniv Arizona, Coll Med
dc.contributor.departmentUniv Arizona, Coll Med, Banner Univ, Med Ctr Tucson, Dept Dermatol & Oncol
dc.identifier.journalCASE REPORTS IN DERMATOLOGY
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal published version
dc.source.journaltitleCASE REPORTS IN DERMATOLOGY
refterms.dateFOA2021-04-03T01:36:40Z


Files in this item

Thumbnail
Name:
508490.pdf
Size:
384.8Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

© 2020 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC).
Except where otherwise noted, this item's license is described as © 2020 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC).